マイクロバイオームの市場規模、シェア、成長分析：製品別、用途別、地域別 - 産業予測 2025～2032年

マイクロバイオームの世界市場規模は2023年に9億1,100万米ドルと評価され、予測期間（2025～2032年）のCAGRは17.7%で、2024年の10億7,225万米ドルから2032年には39億4,918万米ドルに成長する見通しです。

マイクロバイオーム市場は、革新的な製品イントロダクションの流入に加え、マイクロバイオーム療法の研究開発を目的とした戦略的パートナーシップの増加により、大きな成長を遂げています。NIHによるHumanマイクロバイオームプロジェクトのようなイニシアチブは、微生物叢がどのように健康と疾病に影響を与えるかについての理解を深めています。2022年1月のハドソン研究所とBiomeBankとの4年契約のような注目すべき共同研究は、微生物治療法の発見への継続的なコミットメントを浮き彫りにしています。さらに、マイクロバイオームに関連する疾病の発生率が上昇していることも、標的療法への需要をさらに高めています。関心と研究が拡大するにつれ、マイクロバイオーム領域における新たな応用と治療オプションの可能性は増大し続け、この進化する市場の利害関係者に有望な機会を提供しています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制情勢
• ケーススタディ

マイクロバイオーム市場規模：製品別

• 市場概要
• プロバイオティクス
• 食品
• プレバイオティクス
• 医療食品
• その他

マイクロバイオーム市場規模：用途別

• 市場概要
• 治療薬
• 診断薬

マイクロバイオーム市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022～2024年）

主要企業プロファイル

• Seres Therapeutics（USA）
• Ferring Pharmaceuticals（Switzerland）
• BiomeBank（Australia）
• Seed Health（USA）
• International Flavors & Fragrances Inc.（USA）
• Pendulum Therapeutics（USA）
• BioHM Health Inc.（USA）
• Actial Farmaceutica SRL（Italy）
• Optibiotix Health plc（UK）
• Resbiotic（USA）
• Infinant Health Inc.（USA）
• Biogaia AB（Sweden）
• Exegi Pharma LLC（USA）
• Vedanta Biosciences Inc.（USA）
• Enterome（France）
• Yakult（Japan）
• DuPont（USA）
• Metabiomics Corporation（USA）
• ViThera Pharmaceuticals（USA）
• Second Genome（USA）

結論と推奨事項

Global Microbiome Market size was valued at USD 911.0 million in 2023 and is poised to grow from USD 1072.25 million in 2024 to USD 3949.18 million by 2032, growing at a CAGR of 17.7% during the forecast period (2025-2032).

The microbiome market is experiencing significant growth due to rising strategic partnerships aimed at research and development of microbiome therapies, alongside an influx of innovative product introductions. Initiatives like the Human Microbiome Project by the NIH are enhancing our understanding of how microbial flora impacts health and disease. Notable collaborations, such as the four-year agreement between Hudson Institute and BiomeBank in January 2022, highlight the ongoing commitment to discovering microbial treatments. Additionally, the escalating incidence of diseases linked to the microbiome is further fueling the demand for targeted therapies. As interest and research expand, the potential for new applications and treatment options in the microbiome space continues to increase, presenting promising opportunities for stakeholders in this evolving market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Microbiome market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Microbiome Market Segmental Analysis

Global Microbiome Market is segmented by Product, Application and region. Based on Product, the market is segmented into Probiotics, Foods, Prebiotics, Medical food and Others. Based on Application, the market is segmented into Therapeutics and Diagnostics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Microbiome Market

The Global Microbiome market is driven by a heightened emphasis on the development of therapeutics targeting the human microbiome, particularly within the gut. Research has shown the vital role that gut microbiomes play in enhancing the effectiveness of medicinal drugs, with an optimal balance of microorganisms aiding in the treatment of various diseases. This relationship between specific bacteria and disease states paves the way for innovative medication and vaccine development. Significant investments in microbiome research, such as the National Institutes of Health's $215 million for the Human Microbiome Project and substantial EU funding initiatives like MetaHIT and Horizon 2020, underline this growing interest and increase in popularity for microbiome-based treatments.

Restraints in the Global Microbiome Market

The global microbiome market faces significant restraints primarily due to stringent government regulations. Notably, probiotics have yet to be recognized by the FDA as approved live biotherapeutic products, despite the availability of FDA-regulated foods and dietary supplements that contain these live organisms. These products cannot be marketed as effective treatments for diseases, which limits their potential in the marketplace. While some probiotics are currently undergoing clinical trials for potential future approval as biologics, the uncertainty surrounding FDA regulations poses a challenge for investment and research. Stricter regulatory measures could require extensive R&D efforts, discouraging significant investment and potentially stalling market growth.

Market Trends of the Global Microbiome Market

The Global Microbiome market is witnessing a notable trend of increasing collaborations between public and private organizations, driven by the proliferation of small innovative players. This dynamic landscape presents significant growth opportunities for key stakeholders seeking to acquire companies focused on microbiome research to discover new drugs and targets for various health conditions, including obesity, liver disorders, diabetes, and metabolic issues. As major market leaders prioritize strategic alliances and partnerships, the last two years have seen a surge in collaborative efforts to enhance product development pipelines through robust R&D initiatives, indicating a vibrant and evolving market poised for expansion.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies

Global Microbiome Market Size by Product & CAGR (2025-2032)

• Market Overview
• Probiotics
• Foods
• Prebiotics
• Medical food
• Others

Global Microbiome Market Size by Application & CAGR (2025-2032)

• Market Overview
• Therapeutics
• Diagnostics

Global Microbiome Market Size & CAGR (2025-2032)

• North America (Product, Application)
  • US
  • Canada
• Europe (Product, Application)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Application)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Application)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Application)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Seres Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferring Pharmaceuticals (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BiomeBank (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Seed Health (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• International Flavors & Fragrances Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pendulum Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioHM Health Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Actial Farmaceutica SRL (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Optibiotix Health plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Resbiotic (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Infinant Health Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogaia AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exegi Pharma LLC (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vedanta Biosciences Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Enterome (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Yakult (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DuPont (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Metabiomics Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ViThera Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Second Genome (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations